PMV Pharmaceuticals’ (PMVP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $5.00 price objective on the stock. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.03) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.57) EPS.

Several other analysts have also commented on the stock. Craig Hallum started coverage on shares of PMV Pharmaceuticals in a research report on Monday, May 13th. They set a buy rating and a $6.00 price target on the stock. CLSA raised shares of PMV Pharmaceuticals to a strong-buy rating in a research note on Monday, May 13th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, PMV Pharmaceuticals has an average rating of Buy and an average target price of $5.75.

PMV Pharmaceuticals Stock Up 1.3 %

PMV Pharmaceuticals stock opened at $1.55 on Tuesday. The business’s 50-day moving average price is $1.58 and its 200 day moving average price is $1.71. The firm has a market cap of $79.74 million, a price-to-earnings ratio of -1.17 and a beta of 1.53. PMV Pharmaceuticals has a 52 week low of $1.18 and a 52 week high of $7.64.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.32. Equities analysts expect that PMV Pharmaceuticals will post -1.17 EPS for the current year.

Institutional Investors Weigh In On PMV Pharmaceuticals

Several institutional investors have recently bought and sold shares of PMVP. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of PMV Pharmaceuticals during the first quarter valued at approximately $26,000. Tower Research Capital LLC TRC raised its stake in PMV Pharmaceuticals by 344.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,508 shares of the company’s stock valued at $29,000 after purchasing an additional 7,368 shares during the last quarter. Independent Advisor Alliance purchased a new position in PMV Pharmaceuticals in the 4th quarter valued at $39,000. Public Employees Retirement System of Ohio boosted its stake in PMV Pharmaceuticals by 174.2% during the 1st quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock worth $39,000 after purchasing an additional 14,457 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of PMV Pharmaceuticals by 71.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company’s stock worth $73,000 after buying an additional 17,858 shares in the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.